Given that there are 10 other drugs in late-stage development for NASH, in addition to Ocaliva and elafibranor, stakes are high for Intercept. The company has since released a statement emphasizing that it is focusing on educating physicians on the label and appropriate dosing for PBC, in addition to rigorously monitoring patients for liver-related adverse reactions. GlobalData believes that Intercept should plan ahead for similar initiatives regarding dosing of the drug in NASH, as well as work closely with the regulatory authorities to ensure long-term safety of Ocaliva for NASH.